Current advances and future directions in combined hepatocellular and cholangiocarcinoma.
Gastroenterol Rep (Oxf)
; 12: goae031, 2024.
Article
in En
| MEDLINE
| ID: mdl-38628397
ABSTRACT
The low incidence of combined hepatocellular cholangiocarcinoma (cHCC-CCA) is an important factor limiting research progression. Our study extensively included nearly three decades of relevant literature and assembled the most comprehensive database comprising 5,742 patients with cHCC-CCA. We summarized the characteristics, tumor markers, and clinical features of these patients. Additionally, we present the evolution of cHCC-CCA classification and explain the underlying rationale for these classification standards. We reviewed cHCC-CCA diagnostic advances using imaging features, tumor markers, and postoperative pathology, as well as treatment options such as surgical, adjuvant, and immune-targeted therapies. In addition, recent advances in more effective chemotherapeutic regimens and immune-targeted therapies were explored. Furthermore, we described the molecular mutation features and potential specific markers of cHCC-CCA. The prognostic value of Nestin has been proven, and we speculate that Nestin will also play a role in classification and diagnosis. However, further research is needed. Moreover, we believe that the possibility of using machine learning liquid biopsy for preoperative diagnosis and establishing a scoring system are directions for future research.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Gastroenterol Rep (Oxf)
Year:
2024
Document type:
Article
Country of publication:
Reino Unido